IN THE HIGH COURT OF DELHI AT NEW DELHI
PRATHIBA M. SINGH, J.
Master Medhansh Jhawar – Appellant
Versus
Rajesh Bhushan and Others – Respondents
CONT. CAS(C) 415/2022, CM APPL. 18280/2022, W.P.(C) 5315/2020, CM APPL. 19189/2020, 4237/2023, 7519/2023, W.P.(C) 11610/2017, CM APPL. 27637/2018, 44016/2022, W.P.(C) 2943/2020, CM APPLs. 10227/2020, 6633/2022, 7534/2023, W.P.(C) 10782/2020, CM APPL. 33828/2020, W.P.(C) 322/2021, CM APPL. 812/2021, W.P.(C) 1491/2021, CM APPLs. 4291/2021, 8671/2022, W.P.(C) 1511/2021, CM APPL. 4331/2021, 8616/2022, W.P.(C) 1611/2021, CM APPL. 4600/2021, W.P.(C) 3662/2021, CM APPLs. 11103/2021, 25590/2021, 32504/2021, W.P.(C) 3682/2021, CM APPL. 11153/2021, W.P.(C) 3689/2021, CM APPL.11179/2021, W.P.(C) 3706/2021, CM APPL. 11229/2021, W.P. (C) 3707/2021, CM APPL. 11230/2021, W.P.(C) 3729/2021, CM APPL. 11269/2021, W.P.(C) 3737/2021, CM APPL. 11277/2021, W.P.(C) 3859/2021, CM APPL. 11647/2021, W.P.(C) 4045/2021, CM APPL. 12213/2021, W.P.(C) 4067/2021, CM APPL. 12306/2021, W.P.(C) 4259/2021, CM APPL. 12948/2021, W.P.(C) 4304/2021, CM APPL. 13108/2021, W.P.(C) 4551/2021, CM APPL. 13949/2021, W.P.(C) 4812/2021, CM APPL. 14844/2021, W.P.(C) 5394/2021, CM APPL. 16683/2021, W.P.(C) 5395/2021, CM APPL. 16686/2021, W.P.(C) 9684/2021, W.P.(C) 14317/2021, CM APPL. 45148/2021, 14521/2023, W.P.(C) 1182/2022, CM APPL. 3442/2022, W.P.(C) 1054/2023 and CM APPL. 4164/2023, W.P.(C) 1079/2023 and CM APPL. 4248/2023, And, W.P.(C) 2614/2023, W.P.(C) 4495/2023, CM APPL.17190/2023, W.P.(C) 4502/2023, CM APPL.17238/2023, W.P.(C) 4526/2023, CM APPL.17321/2023, W.P.(C) 4535/2023, CM APPL.17331/2023, W.P.(C) 4536/2023, CM APPL.17333/2023, W.P.(C) 4538/2023, CM APPL.17337/2023, W.P.(C) 4539/2023, CM APPL.17340/2023, W.P.(C) 4591/2023, CM APPL. 17548/2023, And, W.P.(C) 5102/2023, CM APPL.19968/2023, W.P.(C) 5726/2023, CM APPL. 22436/2023, W.P.(C) 5753/2023 and CM APPL. 22528/2023
Decided on : 03-05-2023
Rare Diseases - Approval of COE Committee - [W.P.(C) 5315/2020, W.P.(C) 4495/2023, W.P.(C) 4502/2023, W.P.(C) 4526/2023, W.P.(C) 4535/2023, W.P.(C) 4536/2023, W.P.(C) 4538/2023, W.P.(C) 4539/2023, W.P.(C) 4591/2023, W.P.(C) 5102/2023, W.P.(C) 5726/2023, W.P.(C) 5753/2023, CONT. CAS(C) 415/2022, W.P.(C) 4045/2021, W.P.(C) 4067/2021, W.P.(C) 4259/2021, W.P.(C) 4304/2021, W.P.(C) 4551/2021, W.P.(C) 4812/2021, W.P.(C) 5394/2021, W.P.(C) 5395/2021, W.P.(C) 9684/2021, W.P.(C) 14317/2021, W.P.(C) 1182/2022, W.P.(C) 1054/2023, W.P.(C) 1079/2023, W.P.(C) 2614/2023] - The Court approved the constitution of the Centre of Excellence (COE) Rare Diseases Committee by AIIMS, subject to the condition that the decisions shall not be delayed by the size of the Committee.
Fact of the Case:
The petitioners, children suffering from Rare Diseases, sought treatment and availability of medicines, leading to the approval of the COE Committee by the Court.
Finding of the Court:
The Court approved the COE Committee and directed examination of the children within a week for treatment feasibility. It also expressed concern over lapsing budgets and non-release of funds, and compelled the Secretary, Ministry of Health & Family Welfare to remain present in Court.
Issues: Availability of treatment and medicines for children suffering from Rare Diseases, lapsing budgets, and non-release of funds.
Ratio Decidendi: The Court emphasized the need for efficient decision-making by the COE Committee and expressed concern over lapsing budgets and non-release of funds for the treatment of children suffering from Rare Diseases.
Final Decision: The Court approved the COE Committee, directed examination of the children for treatment feasibility, and compelled the Secretary, Ministry of Health & Family Welfare to remain present in Court. It also considered the possibility of issuing a notice of contempt and directed the physical evaluation of children who had been administered medicines.
JUDGMENT :
Prathiba M. Singh, J.
This hearing has been done through hybrid mode.
2. The present batch of petitions has been filed by the Petitioners who are children suffering from Rare Diseases. The case of the Petitioners is that medicines and therapies for the said diseases are exorbitantly expensive. These matters have been heard by the Court from time to time and various directions have been issued for enabling treatment and making medicines available to the Petitioners.
CM APPL. 7519/2023 in W.P.(C) 5315/2020
3. This is an application filed by AIIMS, New Delhi seeking permission to constitute the Centre of Excellence (COE) Rare Diseases Committee in place of the “two-member Rare Disease Committee” which was constituted pursuant to the directions passed by the Court on 23rd March, 2021.
4. It is submitted by Mr. Oberoi, ld. Counsel on behalf of AIIMS as also by Dr. Madulika Kabra, who has appeared virtually before the Court, that after the constitution of the two-member Rare Diseases Committee by this Court, since AIIMS was also notified as a Centre of Excellence under the National Policy for Rare Diseases, 2021, the Committee for Rare Diseases was constituted afresh within AIIMS, New Delhi. As on today, the proposed new COE Committee is as under:
Core Committee:
| S. No. | Name | Designation |
| 1. | Dr. Madhulika Kabra Professor, Deptt. of Pediatrics & Head, Genetics Division | Chairperson |
| 2. | Dr. Arvind Bagga Prof. & Head, Department of Pediatrics | Member |
| 3. | Dr. Sidhartha Satpathy Prof. & Head, Deptt. of Hospital Administration | Member |
| 4. | Dr. Vineet Ahuja Professor, Deptt. of Gastroenterology | Member |
| 5. | Dr. Rakesh Lodha Professor, Deptt. of Pediatrics | Member |
| 6. | Dr. Rajesh Khadgawat Professor, Dept. of Endocrinology | Member |
| 7. | Dr. Tulika Seth Professor, Deptt. of Hematology | Member |
| 8. | Dr. Jitender Sodhi Assoc. Professor, Deptt. of Hosp. Admn. (Representative of M.S.) | Member |
| 9. | Dr. Kanika Jain Asst. Professor, Deptt. of Hosp. Admn. (Representative of Stores) | Member |
| 10. | Financial Advisor or his representative | Member |
| 11. | F&CAO (Hospital Billing Section) | Member |
| 12. | Administrative Officer, Legal Cell | Member |
| 13. | Dr. Neerja Gupta Addl. Professor, Deptt. of Pediatrics | Member Secy. |
5. Upon a query being put to the ld. Counsel and also to Dr. Kabra as to how such a large Committee would be efficient especially in treatment of urgent cases of children with rare diseases, an assurance has been given by Dr. Kabra that the working of this Committee would be efficient and the number of members in the Committee would not in any way act as an impediment in taking quick decisions.
6. It is made clear that the proposal which has been put up by AIIMS has been approved by the Court subject to the condition that the decisions to be taken by the Rare Diseases Committee shall not be delayed or impeded in any manner by the size of the Committee.
7. The Committee is approved in the above terms.
8. The application is disposed of.
W.P.(C) 4495/2023 & CM APPL.17190/2023
W.P.(C) 4502/2023 & CM APPL.17238/2023
W.P.(C) 4526/2023 & CM APPL.17321/2023
W.P.(C) 4535/2023 & CM APPL.17331/2023
W.P.(C) 4536/2023 & CM APPL.17333/2023
W.P.(C) 4538/2023 & CM APPL.17337/2023
W.P.(C) 4539/2023 & CM APPL.17340/2023
W.P.(C) 4591/2023 & CM APPL. 17548/2023
W.P.(C) 5102/2023 & CM APPL.19968/2023
W.P.(C) 5726/2023 & CM APPL. 22436/2023
W.P.(C) 5753/2023 & CM APPL. 22528/2023
9. Issue notice in these petitions. Let the said children be examined in AIIMS within the next one week and a report be filed by the next date of hearing as to the feasibility of providing treatment to them.
10. List on 10th May, 2023 at 3:30 p.m.
CONT. CAS(C) 415/2022 & CM APPL. 18280/2022
W.P.(C) 4045/2021 & CM APPL. 12213/2021
W.P.(C) 4067/2021 & CM APPL. 12306/2021
W.P.(C) 4259/2021 & CM
The Court emphasized the need for efficient decision-making by the COE Committee and expressed concern over lapsing budgets and non-release of funds for the treatment of children suffering from Rare ....
The court emphasized the need for immediate treatment and funding for rare diseases, and referred the matter to the National Consortium for comprehensive recommendations.
The court affirmed that the right to health, as part of the fundamental right to life under Article 21, requires timely access to treatment, especially for children with rare diseases.
The central legal point established in the judgment is the need to facilitate the conduct of clinical trials, streamline the manufacturing and trials process, and ensure the implementation of the Nat....
The fundamental right to health and healthcare under Article 21 of the Constitution necessitates ensuring treatment for Rare Diseases despite exorbitant costs, and the government's obligation to fina....
The government has an obligation to invest in research for indigenous therapies, and the court can direct the commencement of treatment and release of funds for rare diseases treatment under the Rare....
The court prioritized the expedited release of medicines for rare diseases and facilitated discussions and meetings between relevant parties to ensure the availability of treatment for petitioners.
Facilities for treatment of rare diseases would not be in place in the State in the near future without judicial interference.
The right to health is an integral part of the right to life under Article 21 of the Constitution, and the Central and State Governments have a duty to protect the life of citizens, especially childr....
Login now and unlock free premium legal research
Login to SupremeToday AI and access free legal analysis, AI highlights, and smart tools.
Login
now!
India’s Legal research and Law Firm App, Download now!
Copyright © 2023 Vikas Info Solution Pvt Ltd. All Rights Reserved.